Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 28

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 28
---
 CVR no. 2102 3884           |

#### Interim Report for the First Half of 2025
Key Developments to Research and Development Expenses – Second Quarter of 2025

Research and development expenses were $364 million for the second quarter of 2025 compared to $361 million for the second quarter of 2024, an increase of $3 million, or 1%.

Selling, General and Administrative Expenses Selling, general and administrative expenses were $270 million in the first six months of 2025 compared to $243 million in the first six months of 2024. The increase of $27 million, or 11%, was driven primarily by the expansion of Genmab’s global commercialization capabilities, primarily associated with the expansion of Epcoritamab and investment in Rina-S to prepare for the upcoming projected launch.

Selling, general and administrative expenses accounted for 27% of total research and development expenses & selling, general and administrative expenses in the first six months of 2025 compared to 26% for the first six months of 2024.

Key Developments to Selling, General and Administrative Expenses – Second Quarter of 2025

Selling, general and administrative expenses were $144 million for the second quarter of 2025 compared to $129 million for the second quarter of 2024. The increase of $15 million, or 12%, was driven primarily by the expansion of Genmab’s commercialization capabilities.

Acquisition and Integration Related Charges Acquisition and integration related charges for the acquisition of ProfoundBio were $36 million in the first six months of 2024. There were no acquisition and integration related charges in the first six months of 2025.

Key Developments to Acquisition and Integration Related Charges – Second Quarter of 2025

Acquisition and integration related charges for the acquisition of ProfoundBio were $25 million for the second quarter of 2024. There were no acquisition and integration related charges for the second quarter of 2025.

Operating Profit Operating profit was $548 million in the first six months of 2025 compared to $352 million in the first six months of 2024. The increase was driven by the items described above.

Key Developments to Operating Profit - Second Quarter of 2025 Operating profit was $360 million for the second quarter of 2025 compared to $236 million for the second quarter of 2024. The increase was driven by the items described above.

Net Financial Items Financial income and expense